By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
INTRODUCTION
INSULIN LISPRO contains human insulin used to treat type 1 and type 2 diabetes mellitus. Diabetes mellitus is a condition that affects how the body processes glucose.
In Diabetes Mellitus Type 1, the body does not produce enough insulin to regulate blood sugar levels. On the other hand, in Diabetes Mellitus type 2, either the body stops producing enough insulin (a hormone that helps lower blood sugar levels), or there is resistance to insulin action.
INSULIN LISPRO works similarly to the insulin produced by the body. INSULIN LISPRO stops the liver from producing more sugar and also helps move the sugar from the blood into other body tissues where it can be used for energy. Thereby, INSULIN LISPRO helps control blood sugar levels.
INSULIN LISPRO MARKET SIZE AND FORECAST
The Global Insulin Lispro Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
INSULIN LISPRO MARKET NEW PRODUCT LAUNCH
Apollo Pharmacy Insulin Lispro INSULIN LISPRO works by ensuring rapid and consistent sugar control. It facilitates the reuptake of sugar in muscle and fat cells and thus suppresses sugar production in the liver. It helps to decrease blood sugar levels after the intake of meals. It prevents the chances of developing serious complications of diabetes.
Besides this, INSULIN LISPRO can be safely prescribed during the pregnancy as well as lactation stage. INSULIN LISPRO helps in improving the glycemic control, which in turn decreases the risk of progression of complications of diabetes like damage of the retina (retinopathy), impairment of kidney (nephropathy), impairment of nerve cells (neuropathy), delayed wound healing, diabetic foot ulcer and others. INSULIN LISPRO should be administered subcutaneously in the abdomen or thigh region.
Through recombinant DNA technology, the final lysine and proline residues on the C-terminal end of the B-chain are reversed. This modification does not alter receptor binding, but blocks the formation of insulin dimers and hexamers. This allows larger amounts of active monomeric insulin to be immediately available for postprandial injections.
It is a manufactured form of human insulin where the amino acids lysine and proline have been switched at the end of the B chain of the insulin molecule. This switch of amino acids mimics Insulin-like growth factor 1 which also has lysine (K) and proline (P) in that order at positions twenty seven and twenty eight.
INSULIN LISPRO MARKET COMPANY PROFILE
THIS INSULIN LISPRO MARKET REPORT WILL ANSWER FOLLOWING QUESTIONS
